Tarsus Pharmaceuticals Inc
TARS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.5B
Close$
$-40.00
168.8% downside
Current Fair Value
168.8% downsideOvervalued by 168.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.50 Billion |
|---|---|
| Enterprise Value | $2.49 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.59 |
| Beta | 0.5 |
| Outstanding Shares | 42,956,973 |
Return
| Return on Equity | -13.83% |
|---|---|
| Return on Assets | -8.31% |
| Return on Invested Capital | -9.79% |
Valuation & Multiples
| P/E Ratio | -51 |
|---|---|
| PEG | 70.57 |
| Price to Sales | 4.85 |
| Price to Book Ratio | 7.27 |
| Enterprise Value to Revenue | 4.65 |
| Enterprise Value to EBIT | -58.06 |
| Enterprise Value to Net Income | -52 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$149.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$170.02 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 76.33% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.29%▼ 102.22% |
|---|---|
| Total Invested | $88.87M▼ 97.19% |
| Investors Holding | 12▼ 248.00% |
ESG Score
No data
About Tarsus Pharmaceuticals Inc
20 employeesTarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...